Dr Jeffrey Bruce Smaill

BSc(Hons), PhD

Biography

Jeff Smaill obtained his BSc(Hons) and PhD degrees in the field of synthetic organic chemistry from the University of Otago in the laboratory of Professor Peter K Grant. He then completed a postdoctoral fellowship at the University of Cambridge under the supervision of Professor Ian Paterson, developing a biomimetic approach to the total synthesis of the polyether antibiotic Etheromycin. He joined the Auckland Cancer Society Research Centre in 1994 and has been involved in drug development collaborations with Circadian Pharmaceuticals and Pfizer Global Research and Development. He is currently an Associate Investigator of the Maurice Wilkins Centre for Molecular Biodiscovery, a Project Leader on a New Economy Research Fund Programme Grant, a Co-Principle Investigator on a Health Research Council Project Grant and a Named Investigator on a Health Research Council Programme Grant. He is active in a number of medicinal chemistry related research projects.

Dr Smaill has extensive experience in the design and synthesis of ATP-competitive small molecule kinase inhibitors. He has been involved in the elucidation of structure-activity relationships for 4-anilinoquinazolines and 4-anilinopyridopyrimidines as irreversible inhibitors of the Human Epidermal Growth Factor Receptor (HER) family. Culminating in the development of CI-1033 (canertinib dihydrochloride), the first irreversible inhibitor of HER1-4 to enter clinical trials. He has published on 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones and 4-phenylpyrrolocarbazoles as inhibitors of the cell-cycle checkpoint control protein Wee1 and N-phenylbenzimidazoles as inhibitors of the Platelet Derived Growth Factor Receptor (PDGFR). He is currently interested in developing the next generation of bioreductive prodrugs with a focus on using a hypoxia-activated prodrug strategy to impart increased tumour-selectivity to novel multikinase inhibitors.

Research interests

Selected publications and creative works (Research Outputs)

  • Xiang, Q., Wang, C., Zhang, Y., Xue, X., Song, M., Zhang, C., ... Hui, X. (2018). Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer. European journal of medicinal chemistry, 147, 238-252. 10.1016/j.ejmech.2018.01.087
    Other University of Auckland co-authors: Adam Patterson
  • Lu, X., Yu, L., Zhang, Z., Ren, X., Smaill, J. B., & Ding, K. (2018). Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry. Medicinal research reviews10.1002/med.21488
  • Cavazos, A., Ma, H., Han, L., Cai, T., Zhang, Q., Harutyunyan, K., ... Andreeff, M. (2017). Pre-Clinical Activity of SN37169, a Novel Hypoxia-Activated FLT3 Inhibitor Prodrug in FLT3-Mutated AML. Paper presented at 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA. 9 December - 12 December 2017. BLOOD. (pp. 3).
  • Li, X., Guise, C. P., Taghipouran, R., Yosaatmadja, Y., Ashoorzadeh, A., Paik, W.-K., ... Xu, Y. (2017). 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors. European Journal of Medicinal Chemistry, 135, 531-543. 10.1016/j.ejmech.2017.04.049
    Other University of Auckland co-authors: Christopher Guise, Christopher Squire, Adam Patterson, Amir Ashoorzadeh, Yuliana Yosaatmadja
  • Zygouropoulou, M., Kubiak, A. M., Copp, J. N., Dubois, L. J., Mowday, A. M., Guise, C. P., ... Patterson, A. V. (2017). Clostridium as "Trojan Horse" Vectors for Cancer Treatment. Paper presented at 20th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Washington, DC. 10 May - 13 May 2017. MOLECULAR THERAPY. (pp. 1).
    Other University of Auckland co-authors: Christopher Guise, Adam Patterson
  • Mowday, A. M., Guise, C. P., Kubiak, A. M., Minton, N. P., Abbattista, M. R., Lambin, P., ... Patterson, A. V. (2017). Efficacy of a Novel Enzyme/Prodrug Combination for Clostridia Directed Enzyme Prodrug Therapy. Paper presented at 20th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Washington, DC. 10 May - 13 May 2017. MOLECULAR THERAPY. (pp. 2).
    Other University of Auckland co-authors: Christopher Guise, Adam Patterson
  • Guise, C., Abbattista, M., Mowday, A., Ashoorzadeh, A., Bull, M., Silva, S., ... Theys, J. (2017). SN36506: A rationally designed second generation analogue of PR-104 selected for clinical evaluation. Paper presented at 15th International Tumour Microenvironment Workshop, Miami, FL, USA. 27 April - 29 April 2017.
    Other University of Auckland co-authors: Maria Abbattista, Christopher Guise, Amir Ashoorzadeh, Bob Anderson, Jack Flanagan, Kevin Hicks, Adam Patterson, Matthew Bull
  • Mo, C., Zhang, Z., Guise, C. P., Li, X., Luo, J., Tu, Z., ... Ren, X. (2017). 2-Aminopyrimidine derivatives as new selective Fibroblast Growth Factor Receptor 4 (FGFR4) inhibitors. ACS Medicinal Chemistry Letters, 8 (5), 543-548. 10.1021/acsmedchemlett.7b00091
    Other University of Auckland co-authors: Christopher Guise, Adam Patterson

Contact details

Primary office location

M&HS BUILDING 504 - Bldg 504
Level 1, Room 120
85 PARK RD
GRAFTON
AUCKLAND 1023
New Zealand